Medical

An EMA Pharmacovigilance Risk Assessment Committee (PRAC) review of published data from controlled clinical trials, observational studies, and meta-analyses has concluded that all inhaled corticosteroid (ICS) products appear to carry a similar risk of pneumonia… Read more . . .

Sunovion has announced that the GOLDEN-3 and GOLDEN-4 Phase 3 clinical trials of SUN-101 glycopyrrolate inhalation solution for the treatment of moderate-to-very severe COPD both met their primary endpoints. SUN-101, delivered via the PARI eFlow… Read more . . .

Mast Therapeutics has announced that the Duke Clinical Research Institute will serve as the coordinating center for the Heart Failure Clinical Research Network (HFN) as it conducts a Phase 2 study of AIR001 sodium nitrite… Read more . . .

An analysis of data from Boehringer Ingelheim’s WISDOM study showed that withdrawal of ICS for COPD patients using the Spiriva Handihaler tiotropium bromide DPI plus salmeterol is associated with a higher exacerbation rate in patients… Read more . . .

In a leading article published in the Archives of Disease in Childhood, Andrew Bush and Louise Fleming of Royal Brompton Hospital and the National Heart and Lung Institute, Imperial College London assert that “the diagnosis… Read more . . .

Verona Pharma has announced positive data from a Phase 2a study of RPL554, an inhaled PDE3/PDE4 inhibitor for the treatment of acute exacerbations in COPD patients. According to the company, asthma patients who received the… Read more . . .

The US Department of Health and Human Services has announced that a grant of up to $200,000 is available for “Assessment of Intersubject Variability in Small Airway Delivery with Oral Inhalation Drug Products.” One grant… Read more . . .

Sunovion is presenting observational study data at the Hospital Medicine 2016 conference showing that a substantial number of COPD patients are discharged from hospitals with a prescription for a dry powder inhaler despite their inability… Read more . . .

Boehringer Ingelheim has presented data at the 2016 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting showing that the Spiriva Respimat tiotropium bromide soft mist inhaler improves lung function and reduces exacerbations when… Read more . . .